Helle D Zacho

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1959218/publications.pdf

Version: 2024-02-01

63	1,727	394421 19	289244 40
papers	citations	h-index	g-index

65	65	65	2052
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Assessment of ⁶⁸Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. JAMA Oncology, 2019, 5, 856.	7.1	493
2	Diagnostic Accuracy of ⁶⁸Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. JAMA Oncology, 2021, 7, 1635.	7.1	138
3	⁶⁸Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. Journal of Nuclear Medicine, 2017, 58, 1617-1623.	5.0	111
4	Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. Lancet Oncology, The, 2018, 19, e534-e545.	10.7	98
5	Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1884-1897.	6.4	76
6	Three-minute SPECT/CT is sufficient for the assessment of bone metastasis as add-on to planar bone scintigraphy: prospective head-to-head comparison to 11-min SPECT/CT. EJNMMI Research, 2017, 7, 1.	2.5	64
7	PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review. Cancer Imaging, 2020, 20, 10.	2.8	59
8	Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2978-2989.	6.4	58
9	⁶⁸Gaâ€<scp>PSMA PET</scp>/<scp>CT</scp> for the detection of bone metastases in prostate cancer: a systematic review of the published literature. Clinical Physiology and Functional Imaging, 2018, 38, 911-922.	1.2	56
10	Absorption and metabolism of benzoic acid in growing pigs1. Journal of Animal Science, 2009, 87, 2815-2822.	0.5	46
11	Prospective Multicenter Study of Bone Scintigraphy in Consecutive Patients With Newly Diagnosed Prostate Cancer. Clinical Nuclear Medicine, 2014, 39, 26-31.	1.3	37
12	Incidental Detection of Thyroid Metastases From Renal Cell Carcinoma Using 68Ga-PSMA PET/CT to Assess Prostate Cancer Recurrence. Clinical Nuclear Medicine, 2017, 42, 221-222.	1.3	31
13	Added value of 68Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphy. EJNMMI Research, 2020, 10, 31.	2.5	31
14	Diagnostic test accuracy study of F-sodium fluoride PET/CT, Tc-labelled diphosphonate SPECT/CT, and planar bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2017, 7, 218-227.	1.0	31
15	68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancerâ€"a modified protocol compared with the common protocol. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 624-631.	6.4	26
16	Combination of Forced Diuresis with Additional Late Imaging in ⁶⁸Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake. Journal of Nuclear Medicine, 2021, 62, 1252-1257.	5.0	26
17	68Ga-PSMA PET/CT in Patients With Biochemical Recurrence of Prostate Cancer. Clinical Nuclear Medicine, 2018, 43, 579-585.	1.3	24
18	68Ga-PSMA PET/CT compared with MRI/CT and diffusion-weighted MRI for primary lymph node staging prior to definitive radiotherapy in prostate cancer: a prospective diagnostic test accuracy study. World Journal of Urology, 2020, 38, 939-948.	2.2	23

#	Article	IF	Citations
19	Bone Flare to Androgen Deprivation Therapy in Metastatic, Hormone-Sensitive Prostate Cancer on 68Ga-Prostate-Specific Membrane Antigen PET/CT. Clinical Nuclear Medicine, 2018, 43, e404-e406.	1.3	22
20	68Ga-PSMA PET/CT Uptake in Intramuscular Myxoma Imitates Prostate Cancer Metastasis. Clinical Nuclear Medicine, 2017, 42, 487-488.	1.3	19
21	Accuracy of 18F-FDG PET-CT in triaging lung cancer patients with suspected brain metastases for MRI. Nuclear Medicine Communications, 2015, 36, 1084-1090.	1.1	17
22	Observer Agreement and Accuracy of ¹⁸F-Sodium Fluoride PET/CT in the Diagnosis of Bone Metastases in Prostate Cancer. Journal of Nuclear Medicine, 2020, 61, 344-349.	5.0	16
23	Chronic intestinal ischaemia: diagnosis. Clinical Physiology and Functional Imaging, 2008, 28, 71-75.	1.2	15
24	A Comprehensive Safety Evaluation of 68Ga-Labeled Ligand Prostate-Specific Membrane Antigen 11 PET/CT in Prostate Cancer. Clinical Nuclear Medicine, 2017, 42, 520-524.	1.3	14
25	No Added Value of ¹⁸F-Sodium Fluoride PET/CT for the Detection of Bone Metastases in Patients with Newly Diagnosed Prostate Cancer with Normal Bone Scintigraphy. Journal of Nuclear Medicine, 2019, 60, 1713-1716.	5.0	14
26	Tissue viability imaging for assessment of pharmacologically induced vasodilation and vasoconstriction in human skin. Microvascular Research, 2010, 80, 499-504.	2.5	13
27	Observer agreement and accuracy in the evaluation of bone scans in newly diagnosed prostate cancer. Nuclear Medicine Communications, 2015, 36, 445-451.	1.1	13
28	Functional versus radiological assessment of chronic intestinal ischaemia. Clinical Physiology and Functional Imaging, 2010, 30, 116-121.	1.2	10
29	Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study. Urology, 2017, 108, 135-141.	1.0	10
30	Chronic intestinal ischemia and splanchnic blood-flow: Reference values and correlation with body-composition. World Journal of Gastroenterology, 2013, 19, 882.	3.3	10
31	Prospective comparative study of ¹⁸F-sodium fluoride PET/CT and planar bone scintigraphy for treatment response assessment of bone metastases in patients with prostate cancer. Acta OncolÃ³gica, 2018, 57, 1063-1069.	1.8	9
32	Computer-assisted interpretation of planar whole-body bone scintigraphy in patients with newly diagnosed prostate cancer. Nuclear Medicine Communications, 2015, 36, 679-685.	1.1	8
33	18F-fluoride positron emission tomography/computed tomography and bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer patients: study protocol for a multicentre, diagnostic test accuracy study. BMC Cancer, 2016, 16, 10.	2.6	8
34	Risk factors and haemodynamic variables in patients with low toe-brachial index but normal ankle-brachial index. Atherosclerosis, 2019, 289, 21-26.	0.8	8
35	Large pore dermal microdialysis and liquid chromatographyâ€tandem mass spectroscopy shotgun proteomic analysis: a feasibility study. Skin Research and Technology, 2013, 19, 424-431.	1.6	7
36	Safety and tolerability of regadenoson for myocardial perfusion imaging â€“ first Danish experience. Scandinavian Cardiovascular Journal, 2016, 50, 180-186.	1.2	7

#	Article	IF	Citations
37	68Ga-PSMA PET/CT Uptake in the Ureter Caused by Ligand Expression in Urothelial Cancer. Clinical Nuclear Medicine, 2020, 45, e43-e45.	1.3	7
38	Treatment with bone-seeking radionuclides for painful bone metastases in patients with lung cancer: a systematic review. BMJ Supportive and Palliative Care, 2017, 7, bmjspcare-2015-000957.	1.6	6
39	Unexplained Bone Pain Is an Independent Risk Factor for Bone Metastases in Newly Diagnosed Prostate Cancer: A Prospective Study. Urology, 2017, 99, 148-154.	1.0	6
40	Prospective evaluation of computer-assisted analysis of skeletal lesions for the staging of prostate cancer. BMC Medical Imaging, 2017, 17, 40.	2.7	6
41	Validation of contemporary guidelines for bone scintigraphy in prostate cancer staging: A prospective study in patients undergoing radical prostatectomy. Scandinavian Journal of Urology, 2016, 50, 29-32.	1.0	5
42	Observer agreement of treatment responses on planar bone scintigraphy in prostate cancer patients. Nuclear Medicine Communications, 2017, 38, 215-221.	1.1	5
43	Reporting and Handling of Indeterminate Bone Scan Results in the Staging of Prostate Cancer: A Systematic Review. Diagnostics, 2018, 8, 9.	2.6	5
44	Reporting and handling of equivocal imaging findings in diagnostic studies of bone metastasis in prostate cancer. Acta Radiologica, 2020, 61, 1096-1104.	1.1	5
45	Inter- and intraobserver agreement in standard and ultra-fast single-photon emission computed tomography/computed tomography for the assessment of bone metastases. Nuclear Medicine Communications, 2020, 41, 1005-1009.	1.1	5
46	Validity of negative bone biopsy in suspicious bone lesions. Acta Radiologica Open, 2021, 10, 205846012110306.	0.6	5
47	Comparison of two methods based on photoplethysmography for the diagnosis of peripheral arterial disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 622-627.	1.2	4
48	Validation of 99mTechnetium-labeled mebrofenin hepatic extraction method to quantify meal-induced splanchnic blood flow responses using a porcine model. Journal of Applied Physiology, 2012, 112, 877-882.	2.5	3
49	Giant Hepatic Artery Aneurysm. Diagnostics, 2019, 9, 53.	2.6	3
50	Use of ¹⁸F-NaF PET in the staging of skeletal metastases of newly diagnosed, high-risk prostate cancer patients: a nationwide cohort study. BMJ Open, 2022, 12, e058898.	1.9	3
51	68Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review. Molecular and Clinical Oncology, 2017, 7, 67-72.	1.0	2
52	Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography for staging of high-risk prostate cancer. Scandinavian Journal of Urology, 2017, 51, 498-501.	1.0	2
53	Avid 18F-FDG Uptake in Idiopathic Tumoral Calcinosis Mimicking Lymph Node Metastasis. Diagnostics, 2017, 7, 60.	2.6	2
54	The Ability of the Toe-Brachial Index to Predict the Outcome of Treadmill Exercise Testing in Patients with a Normal Resting Ankle-Brachial Index. Annals of Vascular Surgery, 2020, 64, 263-269.	0.9	1

#	Article	IF	Citations
55	Lesion detection in 18F-sodium fluoride bone imaging. Nuclear Medicine Communications, 2021, Publish Ahead of Print, 78-85.	1.1	1
56	The frequency and malignancy rate of incidental focal breast lesions identified by 18F-fluorodeoxyglucose positron emission tomography. Nuclear Medicine Communications, 2021, 42, 93-100.	1.1	1
57	Observer experience and accuracy of 18F-sodium-fluoride PET/CT for the diagnosis of bone metastases in prostate cancer. Nuclear Medicine Communications, 2022, 43, 680-686.	1.1	1
58	Reply by the Authors. Urology, 2017, 104, 243-244.	1.0	0
59	Author Reply. Urology, 2017, 108, 141.	1.0	0
60	Authorsâ€™ reply: PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2307-2308.	6.4	0
61	Reply: Off-Target Report on ¹⁸F-Sodium Fluoride PET/CT for Detection of Skeletal Metastases in Prostate Cancer. Journal of Nuclear Medicine, 2019, 60, 1836-1836.	5.0	0
62	18F-FDG PET/CT in a Case of Urothelial Carcinoma in the Urachus Presenting as Colon Cancer. Diagnostics, 2022, 12, 31.	2.6	0
63	Influence of Prior Imaging Information on Diagnostic Accuracy for Focal Skeletal Processesâ€”A Retrospective Analysis of the Consistency between Biopsy-Verified Imaging Diagnoses. Diagnostics, 2022, 12, 1735.	2.6	0